This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski R, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381: 1535-46. doi: 10.1056/NEJMoa1910836LarkinJChiarion-SileniVGonzalezRGrobJJRutkowskiRLaoCDet alFive-year survival with combined nivolumab and ipilimumab in advanced melanomaN Engl J Med201938115354610.1056/NEJMoa191083631562797Open DOISearch in Google Scholar
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30: 582-8. doi: 10.1093/annonc/mdz011HamidORobertCDaudAHodiFSHwuWJKeffordRet alFive-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001Ann Oncol201930582810.1093/annonc/mdz011650362230715153Open DOISearch in Google Scholar
Robert C, Hwu W-J, Hamid O, Ribas A, Weber JS, Daud AI, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer 2021; 144: 182-91. doi: 10.1016/j.ejca.2020.11.010RobertCHwuW-JHamidORibasAWeberJSDaudAIet alLong-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanomaEur J Cancer20211441829110.1016/j.ejca.2020.11.010838812833360855Open DOISearch in Google Scholar
Hocevar M, Strojan P, Ocvirk J, Peric B, Blatnik O, Luzar B, et al. [Recommendation for the treatment of patients with melanoma]. [Slovenian]. Rebersek M, editor. [cited 2020 Oct 15]. Ljubljana: Institute of Oncology Ljubljana; 2019. Available at: https://www.onko-i.si/fileadmin/onko/datoteke/Strokovna_knjiznica/smernice/Priporocila_za_obravnavo_bolnikov_z_melanomom_2020.pdfHocevarMStrojanPOcvirkJPericBBlatnikOLuzarBet al[Recommendation for the treatment of patients with melanoma]. [Slovenian]. Rebersek M, editor. [cited 2020 Oct 15]LjubljanaInstitute of Oncology Ljubljana2019Available athttps://www.onko-i.si/fileadmin/onko/datoteke/Strokovna_knjiznica/smernice/Priporocila_za_obravnavo_bolnikov_z_melanomom_2020.pdfSearch in Google Scholar
Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, on behalf of the ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1884-901. doi: 10.1093/annonc/mdz411MichielinOvanAkkooi ACJAsciertoPADummerRKeilholzUon behalf of the ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201930188490110.1093/annonc/mdz41131566661Open DOISearch in Google Scholar
NCCN Clinical Practice Guidelines in Oncology, Cutaneous melanoma. Version 4.2020. [cited 2020 Oct 14]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfNCCN Clinical Practice Guidelines in Oncology, Cutaneous melanomaVersion 4.2020. [cited 2020 Oct 14]. Available athttps://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfSearch in Google Scholar
Bisschop C, Wind TT, Blank CU, Koornstra RHT, Kapiteijn E, Van den Eertwegh AJM, et al. Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch Expanded Access Program. J Immunother 2019; 42: 208-14. doi: 10.1097/CJI.0000000000000271BisschopCWindTTBlankCUKoornstraRHTKapiteijnEVanden Eertwegh AJMet alAssociation between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch Expanded Access ProgramJ Immunother2019422081410.1097/CJI.000000000000027131145233Open DOISearch in Google Scholar
Suo AE, Chan Y, Cheung WY, Monzon JG, Smylie M, Walker JWT, et al. Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma. [abstract]. J Clin Oncol 2018; 36 (15 Suppl): e21577. doi: 10.1200/JCO.2018.36.15_suppl.e21577SuoAEChanYCheungWYMonzonJGSmylieMWalkerJWTet alPembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma[abstract]. J Clin Oncol20183615 Supple2157710.1200/JCO.2018.36.15_suppl.e21577Open DOISearch in Google Scholar
Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev 2021; 92: 102134. doi: 10.1016/j.ctrv.2020.102134HussainiSChehadeRBoldtRGRaphaelJBlanchettePMalekiVareki Set alAssociation between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysisCancer Treat Rev20219210213410.1016/j.ctrv.2020.10213433302134Open DOISearch in Google Scholar
Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 2017; 22: 470-9. doi: 10.1634/theoncologist.2016-0419NishijimaTFShacharSSNyropKAMussHBSafety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysisOncologist201722470910.1634/theoncologist.2016-0419538838128275115Open DOISearch in Google Scholar
EMA. Annex I. Summary of product characteristics. Ipilimumab (Yervoy) product information. [cited 2020 Oct 13]. Available at: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-infor-mation_en.pdfEMA. Annex I. Summary of product characteristics. Ipilimumab (Yervoy) product information. [cited 2020 Oct 13]Available athttps://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-infor-mation_en.pdfSearch in Google Scholar
EMA. Annex I. Summary of product characteristics. Pembrolizumab (Keytruda) product information: [cited 2020 Oct 12]. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdfEMA. Annex I. Summary of product characteristicsPembrolizumab (Keytruda) product information: [cited 2020 Oct 12]https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdfSearch in Google Scholar
EMA. Annex I. Summary of product characteristics. Nivolumab (Opdivo) product information: [cited 2020 Oct 11]. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_sl.pdfMA. Annex I. Summary of product characteristicsNivolumab (Opdivo) product information: [cited 2020 Oct 11]https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_sl.pdfSearch in Google Scholar
Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, et al. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience. Radiol Oncol 2020; 54: 119-27. doi: 10.2478/raon-2020-0003HribernikNBocMOcvirkJKnez-ArbeiterJMestiTIgnjatovicMet alRetrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experienceRadiol Oncol2020541192710.2478/raon-2020-0003708741631955148Open DOISearch in Google Scholar
Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol 1989; 7: 136-45; doi: 10.1016/0738-081x(89)90063-1BystrynJCSerum antibodies in vitiligo patientsClin Dermatol198971364510.1016/0738-081x(89)90063-12667738Open DOISearch in Google Scholar
Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, et al. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 2006; 5: 486-92. doi: 10.1016/j.autrev.2006.03.012Oyarbide-ValenciaKvan denBoorn JGDenmanCJLiMCarlsonJMHernandezCet alTherapeutic implications of autoimmune vitiligo T cellsAutoimmun Rev200654869210.1016/j.autrev.2006.03.012346265616920575Open DOISearch in Google Scholar
Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45-51. doi: 10.1001/jamadermatol.2015.2707HuaCBoussemartLMateusCRoutierEBoutrosCCazenaveHet alAssociation of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumabJAMA Dermatol2016152455110.1001/jamadermatol.2015.270726501224Open DOISearch in Google Scholar
Dick J, Lang N, Slynko A, Kopp-Schneider A, Schulz C, Dimitrakopoulou-Strauss A, et al. Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 2016, 8: 1033-44. doi: 10.2217/imt-2016-0083DickJLangNSlynkoAKopp-SchneiderASchulzCDimitrakopoulou-StraussAet alUse of LDH and autoimmune side effects to predict response to ipilimumab treatmentImmunotherapy2016810334410.2217/imt-2016-008327485076Open DOISearch in Google Scholar
Olson D, Luke JJ, Poklepovic AS, Bajaj M, Higgs E, Carll TC, et al. Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial. [abstract]. J Clin Oncol 2020; 38 (Suppl 15): 10004. doi: 10.1200/JCO.2020.38.15_suppl.10004OlsonDLukeJJPoklepovicASBajajMHiggsECarllTCet alSignificant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial[abstract]. J Clin Oncol202038Suppl 151000410.1200/JCO.2020.38.15_suppl.10004Open DOISearch in Google Scholar
Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 2019; 37: 52-60. doi: 10.1200/JCO.18.00204.KlugerHMChiangVMahajanAZitoCRSznolMTranTet alLong-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trialJ Clin Oncol201937526010.1200/JCO.18.00204635477230407895Open DOISearch in Google Scholar
Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19: 672-81. doi: 10.1016/S1470-2045(18)30139-6LongGVAtkinsonVLoSSandhuSGuminskiADBrownMPet alCombination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyLancet Oncol2018196728110.1016/S1470-2045(18)30139-629602646Open DOISearch in Google Scholar
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018; 379: 722-30. doi: 10.1056/NEJMoa1805453TawbiHAForsythPAAlgaziAHamidOHodiFSMoschosSJet alCombined nivolumab and ipilimumab in melanoma metastatic to the brainN Engl J Med20183797223010.1056/NEJMoa1805453801100130134131Open DOISearch in Google Scholar